ANIP
ANI PHARMACEUTICALS INC
$81.68
+0.04%
$1.8B
No data for this timeframe.
Vol
Market Cap$1.8B
Cap SizeSmall Cap
Inst. Holders50 funds
Inst. Value$930.7M
Inst. Activity15 buys / 15 sells
Insider Activity0B / 21S
Insider Net $-$9.0M
Reddit Sentiment50° Neutral
SEC Reports11
Press Releases2
Recent Activity
Jun 11, 2026
SEC
CFO Stephen Carey exercised and sold option shares in a same-day cashless transaction on June 5, and a director sold a s
CLUSTER — Impact 3/10
Jun 8, 2026
Insider
HAUGHEY THOMAS sold 2,000 shares
Director @ $80.88 ($161.8K)
Jun 5, 2026
Insider
CAREY STEPHEN P. sold 3,312 shares
SVP & CFO @ $80.00 ($265.0K)
Jun 5, 2026
Insider
CAREY STEPHEN P. acquired via exercise 3,312 shares
SVP & CFO @ $49.51 ($164.0K)
May 29, 2026
Event
Nabumetone
BOXED WARNING Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause a
May 27, 2026
other
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
<p align="left">PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasda
May 21, 2026
SEC
ANI Pharmaceuticals held its 2026 Annual Meeting on May 21, 2026, where all seven director nominees were elected, Ernst
8-K — Impact 3/10
May 14, 2026
SEC
A cluster of insider sales at ANI Pharmaceuticals, led by CEO Nikhil Lalwani selling $4.27M worth of shares, follows a s
CLUSTER — Impact 4/10
Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$112.71 (Jan 2026)
Current $81.68
Low $100.00
Median $115.00
High $124.00
7 analysts
$100.00
$124.00
Analyst Ratings
5Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 16, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $2.01 ▲ +0.5% | $1.97 — $2.04 | 12% YoY | 6 |
| Next Q | $2.50 ▼ -0.6% | $2.28 — $2.80 | 23% YoY | 6 |
| Current FY | $9.37 ▼ -0.5% | $9.19 — $9.60 | 19% YoY | 6 |
| Next FY | $10.69 | $9.48 — $13.06 | 14% YoY | 7 |
Latest Reports
NEUTRAL
CLUSTER
3/10
CFO Stephen Carey exercised and sold option shares in a same-day cashless transaction on June 5, and a director sold a s
Jun 11, 2026
NEUTRAL
8-K
3/10
ANI Pharmaceuticals held its 2026 Annual Meeting on May 21, 2026, where all seven director nominees were elected, Ernst
May 21, 2026
BULLISH
Press
7/10
ANI Pharmaceuticals announced FDA approval and immediate launch of Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg, t
Apr 8, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $211.3M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $63.3M | — |
| STATE STREET CORP | $59.3M | — |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $43.4M | ADD |
| DIMENSIONAL FUND ADVISORS LP | $40.8M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | HAUGHEY THOMAS | SELL | $161.8K |
| Jun 5, 2026 | CAREY STEPHEN | SELL | $265.0K |
| Jun 5, 2026 | CAREY STEPHEN | M | $164.0K |
| May 21, 2026 | Thoma Jeanne | A | $0.00 |
| May 21, 2026 | TANNENBAUM RENEE | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $930.7M total value (12,103,342 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, STATE.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 2,747,492 | $211.3M | 22.7% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 823,064 | $63.3M | 6.8% | — |
| 3 | STATE STREET CORP | 771,587 | $59.3M | 6.4% | — |
| 4 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 564,360 | $43.4M | 4.7% | ADD +31.4% |
| 5 | DIMENSIONAL FUND ADVISORS LP | 531,190 | $40.8M | 4.4% | — |
| 6 | Nuveen, LLC | 402,357 | $30.9M | 3.3% | — |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 375,965 | $28.9M | 3.1% | — |
| 8 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 327,276 | $25.2M | 2.7% | — |
| 9 | Invesco Ltd. | 324,349 | $24.9M | 2.7% | ADD +70.9% |
| 10 | DEUTSCHE BANK AG\ | 319,675 | $24.6M | 2.6% | ADD +55.4% |
| 11 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 287,563 | $22.1M | 2.4% | — |
| 12 | AMERIPRISE FINANCIAL INC | 270,262 | $20.8M | 2.2% | — |
| 13 | Freestone Grove Partners LP | 254,230 | $19.6M | 2.1% | ADD +80.2% |
| 14 | NOMURA HOLDINGS INC | 237,225 | $18.2M | 2.0% | — |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 234,288 | $18.0M | 1.9% | — |
| 16 | BANK OF MONTREAL /CAN/ | 230,072 | $17.7M | 1.9% | — |
| 17 | TEACHER RETIREMENT SYSTEM OF TEXAS | 220,224 | $16.9M | 1.8% | ADD +45.6% |
| 18 | MORGAN STANLEY | 219,845 | $16.9M | 1.8% | — |
| 19 | GOLDMAN SACHS GROUP INC | 219,755 | $16.9M | 1.8% | — |
| 20 | ROYAL BANK OF CANADA | 213,919 | $16.5M | 1.8% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Invesco Ltd. | ADD | 189,836 | 324,349 | +70.9% | $24.9M | 2026-Q1 |
| Freestone Grove Partners LP | ADD | 141,109 | 254,230 | +80.2% | $19.6M | 2026-Q1 |
| TEACHER RETIREMENT SYSTEM OF TEXAS | ADD | 151,275 | 220,224 | +45.6% | $16.9M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 314,402 | 186,102 | -40.8% | $14.3M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 45,704 | 150,532 | +229.4% | $11.6M | 2026-Q1 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | ADD | 76,180 | 121,459 | +59.4% | $9.3M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | DOUBLED | 7,780 | 109,552 | +1308.1% | $8.4M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 41,801 | 57,168 | +36.8% | $4.4M | 2026-Q1 |
| Gotham Asset Management, LLC | TRIM | 32,842 | 24,095 | -26.6% | $1.9M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | TRIM | 42,440 | 19,700 | -53.6% | $1.5M | 2026-Q1 |
| FMR LLC | ADD | 9,857 | 18,777 | +90.5% | $1.4M | 2026-Q1 |
| Vestmark Advisory Solutions, Inc. | ADD | 11,390 | 16,788 | +47.4% | $1.3M | 2026-Q1 |
| Assenagon Asset Management S.A. | NEAR_EXIT | 89,777 | 15,897 | -82.3% | $1.2M | 2026-Q1 |
| Artemis Investment Management LLP | TRIM | 21,617 | 15,451 | -28.5% | $1.2M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 7,351 | 14,371 | +95.5% | $1.1M | 2026-Q1 |
| EXCHANGE TRADED CONCEPTS, LLC | ADD | 8,226 | 10,791 | +31.2% | $829.8K | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 54 | 9,372 | +17255.6% | $720.7K | 2026-Q1 |
| Neuberger Berman Group LLC | TRIM | 15,250 | 9,035 | -40.8% | $694.8K | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | TRIM | 15,929 | 7,835 | -50.8% | $602.5K | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 22,237 | 7,471 | -66.4% | $574.5K | 2026-Q1 |
| State of Tennessee, Department of Treasury | ADD | 4,027 | 7,327 | +81.9% | $563.4K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | TRIM | 12,900 | 6,700 | -48.1% | $515.2K | 2026-Q1 |
| Amundi | NEAR_EXIT | 65,730 | 4,571 | -93.0% | $351.5K | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | NEAR_EXIT | 78,557 | 4,225 | -94.6% | $324.9K | 2026-Q1 |
| Swiss Life Asset Management Ltd | ADD | 2,668 | 3,404 | +27.6% | $261.8K | 2026-Q1 |
15 unique insiders with 50 transactions. Net insider value: -$9.0M ($0.00 bought, $9.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | HAUGHEY THOMAS | Director | SELL | 2,000 | $80.88 | $161.8K |
| Jun 5, 2026 | CAREY STEPHEN P. | SVP & CFO | SELL | 3,312 | $80.00 | $265.0K |
| Jun 5, 2026 | CAREY STEPHEN P. | SVP & CFO | EXERCISE | 3,312 | $49.51 | $164.0K |
| May 21, 2026 | Thoma Jeanne | Director | AWARD | 4,357 | — | — |
| May 21, 2026 | TANNENBAUM RENEE P | Director | AWARD | 4,357 | — | — |
| May 21, 2026 | Pera Antonio R | Director | AWARD | 4,357 | — | — |
| May 21, 2026 | Leonard Matthew J | Director | AWARD | 4,357 | — | — |
| May 21, 2026 | HAUGHEY THOMAS | Director | AWARD | 4,357 | — | — |
| May 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $78.16 | $39.1K |
| May 13, 2026 | Walsh Patrick D | Director | SELL | 10,000 | $80.63 | $806.3K |
| May 12, 2026 | Gutwerg Ori | SVP, GENERICS | SELL | 2,772 | $79.50 | $220.4K |
| May 12, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | SELL | 459 | $79.21 | $36.4K |
| May 11, 2026 | Lalwani Nikhil | PRESIDENT & CEO | SELL | 55,000 | $77.57 | $4.3M |
| May 11, 2026 | Walsh Patrick D | Director | SELL | 3,973 | $80.75 | $320.8K |
| Apr 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $77.95 | $39.0K |
| Mar 13, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | SELL | 3,162 | $71.64 | $226.5K |
| Mar 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $72.62 | $36.3K |
| Mar 11, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | SELL | 4,772 | $74.91 | $357.5K |
| Mar 9, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | SELL | 5,087 | $74.13 | $377.1K |
| Mar 9, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | SELL | 3,602 | $74.18 | $267.2K |
| Mar 7, 2026 | CAREY STEPHEN P. | SVP & CFO | TAX W/H | 5,150 | $74.04 | $381.3K |
| Mar 7, 2026 | Lalwani Nikhil | PRESIDENT & CEO | TAX W/H | 17,060 | $74.04 | $1.3M |
| Mar 7, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | TAX W/H | 3,314 | $74.04 | $245.4K |
| Mar 7, 2026 | Gutwerg Ori | SVP, GENERICS | TAX W/H | 3,314 | $74.04 | $245.4K |
| Mar 6, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | SELL | 2,121 | $74.22 | $157.4K |
| Mar 6, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | SELL | 1,485 | $75.00 | $111.4K |
| Mar 3, 2026 | Walsh Patrick D | Director | SELL | 6,000 | $74.23 | $445.4K |
| Mar 3, 2026 | Gutwerg Ori | SVP, GENERICS | SELL | 2,060 | $76.50 | $157.6K |
| Feb 28, 2026 | CAREY STEPHEN P. | SVP & CFO | TAX W/H | 2,773 | $73.90 | $204.9K |
| Feb 28, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | TAX W/H | 1,555 | $73.90 | $114.9K |
| Feb 28, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | TAX W/H | 1,555 | $73.90 | $114.9K |
| Feb 28, 2026 | Lalwani Nikhil | PRESIDENT & CEO | TAX W/H | 12,217 | $73.90 | $902.8K |
| Feb 28, 2026 | Gutwerg Ori | SVP, GENERICS | TAX W/H | 2,221 | $73.90 | $164.1K |
| Feb 28, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | TAX W/H | 628 | $73.90 | $46.4K |
| Feb 28, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | TAX W/H | 2,221 | $73.90 | $164.1K |
| Feb 28, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | TAX W/H | 2,221 | $73.90 | $164.1K |
| Feb 26, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | AWARD | 13,895 | $77.15 | $1.1M |
| Feb 26, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | AWARD | 11,116 | $77.15 | $857.6K |
| Feb 26, 2026 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | AWARD | 11,116 | $77.15 | $857.6K |
| Feb 26, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | AWARD | 21,306 | $77.15 | $1.6M |
| Feb 26, 2026 | Lalwani Nikhil | PRESIDENT & CEO | AWARD | 75,592 | $77.15 | $5.8M |
| Feb 26, 2026 | CAREY STEPHEN P. | SVP & CFO | AWARD | 22,233 | $77.15 | $1.7M |
| Feb 26, 2026 | Gutwerg Ori | SVP, GENERICS | AWARD | 12,969 | $77.15 | $1.0M |
| Feb 26, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | AWARD | 6,021 | $77.15 | $464.5K |
| Feb 26, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | AWARD | 10,810 | $77.15 | $834.0K |
| Feb 20, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | SELL | 1,730 | $77.99 | $134.9K |
| Feb 20, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | SELL | 5,323 | $78.02 | $415.3K |
| Feb 19, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | SELL | 2,084 | $77.53 | $161.6K |
| Feb 14, 2026 | CAREY STEPHEN P. | SVP & CFO | TAX W/H | 2,448 | $77.36 | $189.4K |
| Feb 14, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | TAX W/H | 2,403 | $77.36 | $185.9K |
11 SEC filing reports analyzed. Sentiment: 3 bullish, 1 bearish, 0 mixed, 7 neutral. Avg impact: 4.9/10.
NEUTRAL
CLUSTER
3/10
CFO Stephen Carey exercised and sold option shares in a same-day cashless transaction on June 5, and
Jun 11, 2026
NEUTRAL
8-K
3/10
ANI Pharmaceuticals held its 2026 Annual Meeting on May 21, 2026, where all seven director nominees
May 21, 2026
NEUTRAL
CLUSTER
4/10
A cluster of insider sales at ANI Pharmaceuticals, led by CEO Nikhil Lalwani selling $4.27M worth of
May 14, 2026
BULLISH
8-K
7/10
ANI Pharmaceuticals published an updated May 2026 investor presentation via an 8-K (Item 7.01), reit
May 13, 2026
BULLISH
8-K
8/10
ANI Pharmaceuticals reported Q1 2026 revenue of $237.5M (+20.5% YoY) and GAAP diluted EPS of $1.28,
May 8, 2026
BULLISH
PRESS-RELEASE
8/10
ANI Pharmaceuticals reported Q1 2026 adjusted non-GAAP diluted EPS of $2.05, beating the $1.30 conse
May 8, 2026
NEUTRAL
PRESS-RELEASE
3/10
ANI Pharmaceuticals announced it will release its Q1 2026 financial results on May 8, 2026. No finan
Apr 24, 2026
NEUTRAL
8-K
4/10
ANI Pharmaceuticals dismissed EisnerAmper as its auditor and appointed Ernst & Young effective April
Apr 7, 2026
BEARISH
CLUSTER
6/10
Seven corporate insiders at ANI Pharmaceuticals sold shares in the past week, including five open-ma
Mar 13, 2026
NEUTRAL
CLUSTER
5/10
Multiple executives at ANI Pharmaceuticals, including the CEO, CFO, and other senior leaders, engage
Mar 10, 2026
NEUTRAL
CLUSTER
3/10
ANI Pharmaceuticals CFO Stephen P. Carey surrendered 5,150 shares to cover tax obligations in connec
Mar 10, 2026
Historical analyst distribution (last covering-analyst action Jan 2026): 86% buy across 14 analysts — 5 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$112.71 mean target (Jan 2026)
$100.00 Low
$124.00 High
| Metric | Value |
|---|---|
| Current Price | $81.68 |
| Target Low | $100.00 |
| Target Mean | $112.71 |
| Target Median | $115.00 |
| Target High | $124.00 |
| # Analysts | 7 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$2.01 | $1.97 | $2.04 | 11.6% | +0.5% | 1↑ 5↓ | $0.3B | 24.5% | 6 |
| Next Q 2026-09-30 |
$2.50 | $2.28 | $2.80 | 22.6% | -0.6% | 3↑ 3↓ | $0.3B | 30.4% | 6 |
| Current FY 2026-12-31 |
$9.37 | $9.19 | $9.60 | 18.7% | -0.5% | 7↑ 0↓ | $1.1B | 26.5% | 6 |
| Next FY 2027-12-31 |
$10.69 | $9.48 | $13.06 | 14.2% | -0.2% | 2↑ 5↓ | $1.2B | 11.3% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $2.009 | |
| 7d ago | $2.000 | +0.008 |
| 30d ago | $1.998 | +0.010 |
| 60d ago | $2.177 | -0.168 |
| 90d ago | $2.188 | -0.179 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 16, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 10, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 29, 2026
FDA
Nabumetone
BOXED WARNING Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombo
May 27, 2026
other
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
<p align="left">PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that
May 27, 2026
FDA
Sacubitril and Valsartan
BOXED WARNING WARNING: FETAL TOXICITY When pregnancy is detected, discontinue sacubitril and valsartan as soon as possible (5.1) Drugs that act direct
May 27, 2026
FDA
Estradiol Gel, 0.1%, 0.25 mg, 0.25 g per packet, 30 packets per carton, Rx only, Distributed by: ANI Pharmaceuticals, Inc., Baudette, MN 56623. NDC 70954-531-20
Class II: Defective Container; packets were found to be either empty or partially full.
May 20, 2026
FDA
Mirtazapine
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients i
May 8, 2026
earnings
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
<p>PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results
May 8, 2026
earnings_calendar
ANIP Q1 2026 Earnings Scheduled — 2026-05-08
Apr 24, 2026
earnings
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
<p>PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Compan
Apr 20, 2026
fda
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
<p align="justify">PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced
Apr 14, 2026
FDA
Duloxetine
BOXED WARNING WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents,
Apr 13, 2026
other
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
<p align="justify">PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced
Apr 8, 2026
fda
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
<p align="justify">PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced
Apr 7, 2026
fda
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
<p>PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of
Feb 27, 2026
earnings_calendar
ANIP Q4 2025 Earnings After Market Close — 2026-02-27